Acromegaly

Oct. 22, 2025

Research

Mayo Clinic doctors and researchers are studying a variety of diagnostic and treatment topics associated with acromegaly. The pituitary, gonad and adrenal research team in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition — Research focuses its work on conditions of the pituitary gland, the gonads and the adrenal glands. The team's basic science research includes studies of the structure and function of growth hormone-related genes and control of placental growth hormone gene expression. Clinical research activities include investigating new medications to treat acromegaly, hyperaldosteronism and growth hormone deficiency.

Publications

See a list of publications about acromegaly by Mayo doctors on PubMed, a service of the National Library of Medicine.

  1. Health Education & Content Services. Acromegaly. Mayo Clinic; 2023.
  2. Acromegaly. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/endocrine-diseases/acromegaly. Accessed Sept. 5, 2024.
  3. Kellerman RD, et al. Endocrine and metabolic disorders. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Dec. 26, 2020.
  4. Acromegaly. Endocrine Society. https://www.endocrine.org/patient-engagement/endocrine-library/acromegaly. Accessed Sept. 5, 2024.
  5. Melmed S, et al. Treatment of acromegaly. https://www.uptodate.com/contents/search. Accessed Jan. 4, 2021.
  6. Boguslawska A, et al. Genetics of acromegaly and gigantism. Journal of Clinical Medicine. 2021; doi:10.3390/jcm10071377.
  7. Medical review (expert opinion). Mayo Clinic. Sept. 26, 2025.
  8. Gigantism and acromegaly. Merck Manual Professional Version. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/pituitary-disorders/gigantism-and-acromegaly. Accessed Sept. 17, 2025.
  9. Cushing's syndrome. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome. Accessed Sept. 19, 2025.
  10. About Marfan syndrome. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/heart-disease/about/marfan-syndrome.html. Accessed Sept. 19, 2025.
  11. Paget's disease of bone. American Academy of Orthopaedic Surgeons. https://orthoinfo.aaos.org/en/diseases--conditions/pagets-disease-of-bone. Accessed Sept. 19, 2025.
  12. Bacino CA, et al. Achondroplasia. https://www.uptodate.com/contents/search. Accessed Sept. 19, 2025.
  13. Weaver syndrome. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/weaver-syndrome/. Accessed Sept. 18, 2025.
  14. Alnaaim S, et al. The potential link between acromegaly and risk of acute ischemic stroke in patients with pituitary adenoma: A new perspective. Acta Neurologica Belgica. 2024; doi:10.1007/s13760-023-02354-3.
  15. Demarchis L, et al. Cancer screening in patients with acromegaly: A plea for a personalized approach and international registries. Reviews in Endocrine and Metabolic Disorders. 2025; doi:10.1007/s11154-025-09957-6.
  16. Kerbel J, et al. Real world data on the epidemiology, diagnosis, and treatment of acromegaly: A registries-based approach. Archives of Medical Research. 2023; doi:10.1016/j.arcmed.2023.102856.
  17. Gadelha MR, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. Journal of Clinical Endocrinology & Metabolism. 2025; doi:10.1210/clinem/dgae385.
  18. Melmed S, et al. Clinical biology of the pituitary adenoma. Endocrine Reviews. 2022; doi:10.1210/endrev/bnac010.
  19. Araujo-Castro M, et al. Differences between GH- and PRL-cosecreting and GH-secreting pituitary adenomas: A series of 604 cases. The Journal of Clinical Endocrinology & Metabolism. 2024;109:e2178.
  20. FDA approves new treatment for acromegaly, a rare endocrine disorder. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-acromegaly-rare-endocrine-disorder. Accessed Sept. 30, 2025.